The United States will share COVID-19 prevention, diagnosis and treatment technologies with poor countries.
US government simplifies access to vaccine production technologies, COVID-19 drugs and diagnostic tools for low- and middle-income countries.
The US government has signed an agreement to transfer inventions from the World Health Organization (WHO), funded from the federal budget. WHO will then license the non-profit Patent Pool of Medicines (MPP), which in turn will transfer the technology to specific manufacturers.
Established in 2010, MPP now has patent agreements on several HIV drugs and recently added two drugs for the treatment of COVID-19: Paxlovid from Pfizer and molnupiravir from Merck & Co.
The new agreement also applies to inventions used by companies that produce existing vaccines against COVID-19. Companies can also use these technologies to create new products.
Read also: North Korea first reports death from COVID-19
MPP enters into agreements with drug manufacturers that allow companies with least developed countries pay the lowest royalties, and some do not pay at all.
The World Health Organization has officially identified the domestic pharmaceutical company Darnytsia as the only one in Ukraine that will receive vaccine production technology < from COVID-19 based on mRNA. To date, Ukraine does not produce vaccines against any disease.
